Harbor Capital Advisors Inc. Increases Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX)

Harbor Capital Advisors Inc. lifted its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 15.8% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 74,907 shares of the company’s stock after purchasing an additional 10,243 shares during the period. Harbor Capital Advisors Inc.’s holdings in Vaxcyte were worth $6,132,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the company. Blue Trust Inc. increased its position in shares of Vaxcyte by 33.5% in the third quarter. Blue Trust Inc. now owns 371 shares of the company’s stock worth $42,000 after acquiring an additional 93 shares in the last quarter. Nisa Investment Advisors LLC increased its holdings in Vaxcyte by 5.2% in the 3rd quarter. Nisa Investment Advisors LLC now owns 2,209 shares of the company’s stock valued at $252,000 after purchasing an additional 110 shares in the last quarter. CIBC Asset Management Inc raised its position in Vaxcyte by 3.6% in the third quarter. CIBC Asset Management Inc now owns 3,136 shares of the company’s stock valued at $358,000 after purchasing an additional 110 shares during the period. Amalgamated Bank lifted its stake in shares of Vaxcyte by 4.2% during the second quarter. Amalgamated Bank now owns 3,759 shares of the company’s stock worth $284,000 after purchasing an additional 150 shares in the last quarter. Finally, Riverview Trust Co purchased a new stake in shares of Vaxcyte in the third quarter worth about $27,000. 96.78% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Vaxcyte

In other news, CFO Andrew Guggenhime sold 42,000 shares of the company’s stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $115.39, for a total transaction of $4,846,380.00. Following the completion of the transaction, the chief financial officer now directly owns 90,383 shares of the company’s stock, valued at approximately $10,429,294.37. This represents a 31.73 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Jim Wassil sold 8,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $83.66, for a total value of $669,280.00. Following the completion of the sale, the chief operating officer now directly owns 205,695 shares in the company, valued at approximately $17,208,443.70. This trade represents a 3.74 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 113,732 shares of company stock worth $11,730,787. 3.10% of the stock is currently owned by corporate insiders.

Vaxcyte Price Performance

NASDAQ PCVX opened at $81.08 on Friday. The company’s fifty day moving average price is $90.20 and its two-hundred day moving average price is $93.26. The company has a market capitalization of $10.11 billion, a price-to-earnings ratio of -17.63 and a beta of 0.98. Vaxcyte, Inc. has a 12 month low of $58.10 and a 12 month high of $121.06.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.27. During the same period last year, the company earned ($0.91) earnings per share. As a group, analysts anticipate that Vaxcyte, Inc. will post -4.14 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on PCVX shares. Needham & Company LLC reissued a “buy” rating and set a $140.00 price target on shares of Vaxcyte in a research report on Wednesday, November 6th. Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Finally, The Goldman Sachs Group began coverage on shares of Vaxcyte in a research note on Friday, December 20th. They set a “buy” rating and a $135.00 price target on the stock. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Vaxcyte currently has an average rating of “Buy” and a consensus target price of $145.71.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.